Genentech announced results from its Phase 3 CLEOPATRA study of pertuzumab and trastuzumab (Herceptin; Genentech) plus docetaxel chemotherapy for the treatment of patients with HER2-positive metastatic breast cancer (mBC). CLEOPATRA (CLinical Evaluation Of Pertuzumab And TRAstuzumab) was a randomized, double-blind, placebo-controlled trial with a primary endpoint of progression-free survival. This endpoint was met and patients receiving pertuzumab and trastuzumab plus docetaxel lived significantly longer than people who received only Herceptin and docetaxel.
Pertuzumab, a monoclonal antibody, is an investigational HER2-targeted medicine called a HER2 dimerization inhibitor.
For more information call (800) 821-8590 or visit www.gene.com.